Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Why this matters: Three distinct signals hit Procter & Gamble within 72 hours. The cost to borrow spiked sharply, options positioning shifted, and the short book continued its retreat. Read together, they tell a more nuanced story than any one signal suggests alone.
Cost to borrow rose 134% over the past week to 0.40%. That sounds alarming. It isn't — not here.
The absolute level remains trivially cheap. At 0.40%, borrowing P&G shares costs less than a rounding error for most institutional short sellers. The prior week's reading of 0.17% was itself unusually low. The bounce is a reversion, not a signal of tightening supply.
Availability confirms this. There are 2.1 billion shares available to lend. Against 24.5 million shares currently shorted, that leaves the lending market extraordinarily loose. The cost move reflects repricing at the margin — not any constraint on borrowing.
Short interest fell 10% week-over-week to 1.05% of free float. That is the lowest level since early July. The August 11 short build — flagged in last week's note — is now fully unwound.
At 1.05% of float, the short book is too small to drive meaningful price dynamics in either direction. The ORTEX short score has slipped from 31.1 to 30.1 over the past ten days, consistent with a gradual pressure release rather than anything more dramatic.
Earlier in the week, the put-call ratio hit 0.74 — a three-month high. By August 27 it had pulled back to 0.65, sitting just below the 20-day mean of 0.67. The z-score is -1.1, meaning options demand has actually drifted modestly below its recent average.
The spike and retreat suggests hedging activity around last Tuesday's price weakness, not a sustained shift in sentiment. The 52-week PCR range runs from 0.59 to 1.11 — the current reading sits close to the calm end.
Two downgrades landed since late July. Argus Research cut to Hold on August 7. HSBC downgraded to Hold and slashed its target from $182 to $149 on July 30. The consensus price target sits at $160.61 against a current price of $143.14 — a 12% gap that reflects more uncertainty than conviction on either side.
The October 16 earnings date is the next hard catalyst. That is seven weeks away.
See the live data behind this article on ORTEX.
Open PG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
